Patients with Better Vision to be Enrolled in ACT’s Clinical Trials
for Macular Degeneration

Patients with 20/100 Vision Will Now be Eligible for Enrollment,
Expanding Patient Base and Potentially Accelerating Pace of Trials

January 22, 2013 08:30 AM Eastern Daylight Time

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB:
ACTC or the “Company”), a leader in the field of regenerative
medicine, announced today that it is amending the patient treatment
protocol for the remainder of the Company’s Phase I clinical trials for
Stargardt’s macular dystrophy (SMD) and dry age-related macular
degeneration (dry AMD) currently being conducted in the U.S. and will
also submit an amendment in Europe for the SMD trial being conducted
there. Patients with better vision, a visual acuity of 20/100, will be
eligible for enrollment in the remainder of the trials. By treating
patients earlier in the course of the disease, the Company believes that
the amended patient protocol will have a more significant impact on
photoreceptor rescue and visual function. In previous protocols, only
SMD patients with a visual acuity no better than hand movement in the
treated eyes and dry AMD patients with a visual acuity of 20/400 were
eligible.

“Not only does it have the potential to accelerate
the road to the completion of Phase I, but having a more diverse patient
population could also provide additional clinical insights.”

“Having recently reached the halfway
point in our three clinical trials for macular degeneration, now is
an opportune time to pursue modifications which could help accelerate
the pace of all three trials,” said Gary Rabin, chairman and CEO. “The
advanced age of many of our enrolled patients has tended to limit the
pace at which we are able to enroll and treat them, since other,
unrelated health complications tend to come up more frequently in the
elderly. Patients with better vision tend to be younger on average.”

The Company plans to institute the amended patient protocols upon
receipt of Institutional Review Board (IRB) approval from each of the
clinical sites, for the second half of all the clinical trials.

“We are pleased to be able to expand patient enrollment in all three of
our ongoing clinical trials,” said Robert Lanza, M.D., ACT’s chief
scientific officer. “Not only does it have the potential to accelerate
the road to the completion of Phase I, but having a more diverse patient
population could also provide additional clinical insights.”

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying
cellular technology in the field of regenerative medicine. For more
information, visit www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and
operating results, future growth in research and development programs,
potential applications of our technology, opportunities for the company
and any other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not statements of historical
fact (including statements containing the words “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates,” and similar expressions)
should also be considered to be forward-looking statements. There are a
number of important factors that could cause actual results or events to
differ materially from those indicated by such forward-looking
statements, including: limited operating history, need for future
capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and
economic conditions generally. Additional information on potential
factors that could affect our results and other risks and uncertainties
are detailed from time to time in the company’s periodic reports,
including the report on Form 10-K for the year ended December 31, 2011.
Forward-looking statements are based on the beliefs, opinions, and
expectations of the company’s management at the time they are made, and
the company does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the
time they are made, and the company does not assume any obligation to
update its forward-looking statements if those beliefs, opinions,
expectations, or other circumstances should change. There can be no
assurance that the Company’s clinical trials will be successful.

Recent Stories

MARLBOROUGH, Mass.--(EON: Enhanced Online News)--Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today will host a conference call on M... more »

MARLBOROUGH, Mass.--(EON: Enhanced Online News)--Advanced Cell Technology, Inc. (“ACT”)(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that it has entered into a $30 m... more »